PMID- 24737200
OWN - NLM
STAT- MEDLINE
DCOM- 20150619
LR  - 20151119
IS  - 1099-1263 (Electronic)
IS  - 0260-437X (Linking)
VI  - 34
IP  - 11
DP  - 2014 Nov
TI  - Serum enhanced cytokine responses of macrophages to silica and iron oxide 
      particles and nanomaterials: a comparison of serum to lung lining fluid and 
      albumin dispersions.
PG  - 1177-87
LID - 10.1002/jat.2998 [doi]
AB  - The potential hazard to humans exposed to nanomaterials such as silica and iron 
      oxide was investigated using an in vitro macrophage cell culture system. 
      Amorphous silica and iron oxide particles and nanomaterials (NMs) were dispersed 
      in cell culture medium supplemented with either bovine serum albumin (BSA), lung 
      lining fluid (LLF) or serum, in order to mimic the body fluids encountered during 
      different routes of exposure in the body. End points investigated included 
      macrophage viability and cytokine production. Silica NMs and particles (50 and 
      200 nm, respectively) were unmodified (plain) or aminated (NH2 ). Iron oxide NMs 
      and particles, Fe3 O4 45 nm and Fe2 O3 280 nm were also used in this study. 
      Silica particles and NMs induced a dose-dependent increase in cytotoxicity as 
      measured by lactate dehydrogenase (LDH) release. Serum enhanced silica-induced 
      interleukin (IL)-6, IL-10, IL-1beta and MCP-1 release, whereas albumin partially 
      inhibited MCP-1 release. Aminated silica, 50 nm was more potent than the 200-nm 
      particles at inducing monocyte chemoattractant protein-1 (MCP-1) production when 
      dispersed in medium or LLF, suggesting a size specific effect for these particles 
      and this cytokine. Iron oxide particles were relatively inert compared with the 
      silica particles and NMs; however, serum and albumin did affect cytokine release 
      in some treatments. In conclusion, the data suggests that serum, compared with 
      medium, BSA and LLF is very potent at enhancing macrophage responses to silica 
      and iron oxide particles and NMs. Size was only influential in LLF for a limited 
      number of parameters, whereas surface chemistry was not of consequence in this in 
      vitro macrophage system.
CI  - Copyright (c) 2014 John Wiley & Sons, Ltd.
FAU - Brown, David M
AU  - Brown DM
AD  - School of Life sciences, Heriot-Watt University, Riccarton, Edinburgh, EH14 4AS, 
      UK.
FAU - Johnston, Helinor
AU  - Johnston H
FAU - Gubbins, Eva
AU  - Gubbins E
FAU - Stone, Vicki
AU  - Stone V
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20140416
PL  - England
TA  - J Appl Toxicol
JT  - Journal of applied toxicology : JAT
JID - 8109495
RN  - 0 (Albumins)
RN  - 0 (CCL2 protein, human)
RN  - 0 (Chemokine CCL2)
RN  - 0 (Cytokines)
RN  - 0 (Ferric Compounds)
RN  - 0 (Interleukin-1beta)
RN  - 0 (Interleukin-6)
RN  - 130068-27-8 (Interleukin-10)
RN  - 1K09F3G675 (ferric oxide)
RN  - 7631-86-9 (Silicon Dioxide)
RN  - EC 1.1.1.27 (L-Lactate Dehydrogenase)
SB  - IM
MH  - Albumins/*metabolism
MH  - Animals
MH  - Body Fluids/chemistry
MH  - Chemokine CCL2/blood
MH  - Cytokines/*blood
MH  - Dose-Response Relationship, Drug
MH  - Ferric Compounds/*toxicity
MH  - Humans
MH  - Interleukin-10/blood
MH  - Interleukin-1beta/blood
MH  - Interleukin-6/blood
MH  - L-Lactate Dehydrogenase/metabolism
MH  - Lung/*drug effects/metabolism
MH  - Macrophages/drug effects
MH  - Male
MH  - Nanostructures/chemistry/*toxicity
MH  - Particle Size
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Silicon Dioxide/*toxicity
OTO - NOTNLM
OT  - Cytokine
OT  - Dispersant
OT  - Iron oxide
OT  - J774
OT  - Nanomaterials
OT  - Silica
EDAT- 2014/04/17 06:00
MHDA- 2015/06/20 06:00
CRDT- 2014/04/17 06:00
PHST- 2013/11/27 00:00 [received]
PHST- 2014/01/29 00:00 [revised]
PHST- 2014/01/29 00:00 [accepted]
PHST- 2014/04/17 06:00 [entrez]
PHST- 2014/04/17 06:00 [pubmed]
PHST- 2015/06/20 06:00 [medline]
AID - 10.1002/jat.2998 [doi]
PST - ppublish
SO  - J Appl Toxicol. 2014 Nov;34(11):1177-87. doi: 10.1002/jat.2998. Epub 2014 Apr 16.